Novartis AG Says Biosimilar Shows Similar Efficacy As Amgen’s Neupogen

December 8, 2014 1:40 PM

3 0

Novartis released positive data for its experimental biosimilar of Amgen’s Neupogen today, which shows the biosimilar having similar efficacy against neutropenia in breast cancer patients

Novartis AG (ADR) (NYSE:NVS) reported top-line results today for a Phase III study, called PIONEER, of its filgrastim biosimilar of Amgen, Inc.’s (NASDAQ:AMGN) Neupogen, a white blood cells booster. Novartis’ generic drug unit, Sandoz, announced that the biosimilar demonstrated similar efficacy as t...

Read more

To category page

Loading...